Cargando…

Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use

Drug-induced liver injury (DILI) is a phenomenon that occurs with nearly all classes of medications. Cholestatic DILI represents a fraction of these cases and can present as bland cholestasis, cholestatic hepatitis, secondary sclerosis cholangitis, and vanishing bile duct syndrome. Risk factors have...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Kevin, Moga, Tiberiu, Nallapeta, Naren S, Duve, Robert, Miranda, Clive J, Ismail, Mayada, Mahl, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815788/
https://www.ncbi.nlm.nih.gov/pubmed/36620795
http://dx.doi.org/10.7759/cureus.32262
_version_ 1784864396061704192
author Yang, Kevin
Moga, Tiberiu
Nallapeta, Naren S
Duve, Robert
Miranda, Clive J
Ismail, Mayada
Mahl, Thomas
author_facet Yang, Kevin
Moga, Tiberiu
Nallapeta, Naren S
Duve, Robert
Miranda, Clive J
Ismail, Mayada
Mahl, Thomas
author_sort Yang, Kevin
collection PubMed
description Drug-induced liver injury (DILI) is a phenomenon that occurs with nearly all classes of medications. Cholestatic DILI represents a fraction of these cases and can present as bland cholestasis, cholestatic hepatitis, secondary sclerosis cholangitis, and vanishing bile duct syndrome. Risk factors have been identified for cholestatic DILI, including older age, genetic determinants, and certain medications such as amoxicillin-clavulanate. Here, we describe a complicated case of severe cholestatic DILI secondary to cephalosporin use. A 27-year-old female presented to the hospital initially with fever and abdominal pain for four weeks after an emergency C-section for pre-eclampsia and hemolysis, elevated liver enzymes, lowered platelets (HELLP) syndrome. She was found to have a retroperitoneal abscess and underwent bilateral drain placement. She was initially started on cefazolin, and then coverage was broadened to cefepime. Shortly after, alkaline phosphatase (ALP) rose and peaked at 3498 IU/L, with aspartate aminotransferase (AST) and alanine transaminase (ALT) elevated at 274 IU/L and 122 IU/L, respectively. Extensive testing for secondary causes and a liver biopsy were consistent with DILI. Liver enzymes down-trended with the cessation of cefepime. This case report highlights that prompt recognition of the culprit medication is paramount to recovering normal liver function.
format Online
Article
Text
id pubmed-9815788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98157882023-01-06 Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use Yang, Kevin Moga, Tiberiu Nallapeta, Naren S Duve, Robert Miranda, Clive J Ismail, Mayada Mahl, Thomas Cureus Gastroenterology Drug-induced liver injury (DILI) is a phenomenon that occurs with nearly all classes of medications. Cholestatic DILI represents a fraction of these cases and can present as bland cholestasis, cholestatic hepatitis, secondary sclerosis cholangitis, and vanishing bile duct syndrome. Risk factors have been identified for cholestatic DILI, including older age, genetic determinants, and certain medications such as amoxicillin-clavulanate. Here, we describe a complicated case of severe cholestatic DILI secondary to cephalosporin use. A 27-year-old female presented to the hospital initially with fever and abdominal pain for four weeks after an emergency C-section for pre-eclampsia and hemolysis, elevated liver enzymes, lowered platelets (HELLP) syndrome. She was found to have a retroperitoneal abscess and underwent bilateral drain placement. She was initially started on cefazolin, and then coverage was broadened to cefepime. Shortly after, alkaline phosphatase (ALP) rose and peaked at 3498 IU/L, with aspartate aminotransferase (AST) and alanine transaminase (ALT) elevated at 274 IU/L and 122 IU/L, respectively. Extensive testing for secondary causes and a liver biopsy were consistent with DILI. Liver enzymes down-trended with the cessation of cefepime. This case report highlights that prompt recognition of the culprit medication is paramount to recovering normal liver function. Cureus 2022-12-06 /pmc/articles/PMC9815788/ /pubmed/36620795 http://dx.doi.org/10.7759/cureus.32262 Text en Copyright © 2022, Yang et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Gastroenterology
Yang, Kevin
Moga, Tiberiu
Nallapeta, Naren S
Duve, Robert
Miranda, Clive J
Ismail, Mayada
Mahl, Thomas
Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
title Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
title_full Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
title_fullStr Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
title_full_unstemmed Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
title_short Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
title_sort severe cholestatic drug-induced liver injury with cephalosporin use
topic Gastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815788/
https://www.ncbi.nlm.nih.gov/pubmed/36620795
http://dx.doi.org/10.7759/cureus.32262
work_keys_str_mv AT yangkevin severecholestaticdruginducedliverinjurywithcephalosporinuse
AT mogatiberiu severecholestaticdruginducedliverinjurywithcephalosporinuse
AT nallapetanarens severecholestaticdruginducedliverinjurywithcephalosporinuse
AT duverobert severecholestaticdruginducedliverinjurywithcephalosporinuse
AT mirandaclivej severecholestaticdruginducedliverinjurywithcephalosporinuse
AT ismailmayada severecholestaticdruginducedliverinjurywithcephalosporinuse
AT mahlthomas severecholestaticdruginducedliverinjurywithcephalosporinuse